Pyrimidine Metabolism and Disorders

De Novo Pyrimidine Synthesis - Building Blocks Anew

• Synthesizes pyrimidine ring (U, C, T) from basic precursors.
• Precursors: Glutamine, $CO_2$, Aspartate. 📌 Mnemonic: Gluttonous Carbs and Asparagus.
• Location: Primarily Cytosol; Dihydroorotate Dehydrogenase is mitochondrial.
• Key Regulatory Enzyme: Carbamoyl Phosphate Synthetase II (CPS II).
  • Activated by: ATP, PRPP.
  • Inhibited by: UTP (end-product).
• End Product: Uridine Monophosphate (UMP) → other pyrimidines.
• Multifunctional Enzymes (Eukaryotes):
  • CAD protein: CPS II, Aspartate Transcarbamoylase (ATCase), Dihydroorotase.
  • UMP Synthase: Orotate Phosphoribosyltransferase (OPRT), OMP Decarboxylase.

⭐ Orotic aciduria, a disorder of pyrimidine synthesis, results from deficiency of UMP synthase, leading to ↑ orotic acid in urine.

Pyrimidine Salvage & Degradation - Recycle or Trash

• Salvage Pathway (Recycle):

  • Reutilizes pyrimidine bases (U, T, C) to form nucleotides.
  • Enzymes:
    • Thymidine kinase (TK): Thymidine + ATP → TMP.
    • Uridine-cytidine kinase (UCK): Uridine/Cytidine + ATP → UMP/CMP.
    • Pyrimidine phosphoribosyltransferase: Uracil + PRPP → UMP.
  • Energy-efficient alternative to de novo synthesis.

• Degradation Pathway (Trash):

  • Pyrimidine rings catabolized to water-soluble products.
  • Cytosine/Uracil → $β$-Alanine, $NH_3$, $CO_2$.
  • Thymine → $β$-Aminoisobutyrate (BAIBA), $NH_3$, $CO_2$.
  • Excreted in urine; no uric acid produced. ⭐ > Increased beta-Aminoisobutyrate (BAIBA) excretion suggests high DNA turnover (e.g., leukemia, post-chemotherapy).
  • Dihydropyrimidine Dehydrogenase (DPD) is crucial; deficiency causes toxicity with $5-FU$.

Regulation of Pyrimidine Metabolism - Pathway Patrol

• Primary Control: Cytosolic Carbamoyl Phosphate Synthetase II (CPS II).
  • Activators: ATP, PRPP.
  • Inhibitor: UTP (end-product feedback). 📌 "CUT Pye": UTP inhibits.
• OMP Decarboxylase: Inhibited by UMP.
• Ribonucleotide Reductase (RNR): Converts NDPs $\rightarrow$ dNDPs.
  • Activity: ATP (+), dATP (-).
  • Specificity: dNTPs balance dNTP pool.
• CAD Protein (Eukaryotes): Multifunctional enzyme (CPS II, Aspartate Transcarbamoylase, Dihydroorotase). CPS II is key regulatory site.

⭐ CPS II is the rate-limiting and major regulated enzyme in de novo pyrimidine synthesis in humans; it is allosterically inhibited by UTP and activated by ATP and PRPP.

Pyrimidine Disorders & Drugs - Clinical Crisis Control

• Orotic Aciduria:
  • Defect: UMP synthase (Autosomal Recessive); results in ↓ UMP.
  • Clinical Triad: Megaloblastic anemia (B12/folate resistant), failure to thrive (FTT), orotic acid crystalluria (orange crystals in diaper). Crucially, normal ammonia levels.
  • 📌 Mnemonic: "Old Rats Often Try Interfering Cats" (Orotic acid, Resistant anemia, OMP decarboxylase/Orotate phosphoribosyltransferase, Treat with Uridine, Immune deficiency, Crystals)
  • Treatment: Uridine monophosphate (UMP) or oral uridine triacetate (bypasses enzymatic defect).
• Pharmacological Interventions (Pyrimidine Antagonists):
  • Leflunomide: Inhibits dihydroorotate dehydrogenase (DHODH). Used in rheumatoid arthritis.
  • Methotrexate (MTX): Inhibits dihydrofolate reductase (DHFR) → ↓ Tetrahydrofolate (THF) → ↓ dTMP synthesis.
  • 5-Fluorouracil (5-FU) & Capecitabine (oral prodrug):
    • Mechanism: 5-FU converted to 5-FdUMP, which covalently inhibits thymidylate synthase → "thymineless death".
    • Enhancement: Leucovorin (folinic acid) potentiates 5-FU activity.
  • Hydroxyurea: Inhibits ribonucleotide reductase (RNR) → ↓ formation of deoxynucleotides.
• Toxicity Management & Rescue:
  • 5-FU/Capecitabine toxicity: Uridine triacetate.
  • MTX toxicity: Leucovorin rescue (replenishes folate pool).

⭐ Orotic aciduria is distinguished by megaloblastic anemia unresponsive to vitamin B12 or folic acid, alongside normal blood ammonia levels, differentiating it from urea cycle disorders like OTC deficiency which present with hyperammonemia.

High‑Yield Points - ⚡ Biggest Takeaways

• De novo pyrimidine synthesis starts with carbamoyl phosphate & aspartate; CPS II (cytosolic) is rate-limiting.
• Orotic aciduria: UMP synthase deficiency; ↑ orotic acid, megaloblastic anemia, normal ammonia. Treat with uridine.
• Leflunomide inhibits dihydroorotate dehydrogenase.
• 5-Fluorouracil (5-FU), via FdUMP, inhibits thymidylate synthase, ↓ dTMP.
• Hydroxyurea inhibits ribonucleotide reductase, blocking conversion of NDPs to dNDPs.
• Methotrexate inhibits dihydrofolate reductase, reducing THF for pyrimidine (and purine) synthesis.